Navigation Links
SuperGen to Present at FBR Capital Markets 12th Annual Spring Investor Conference on May 29, 2008
Date:5/22/2008

DUBLIN, Calif., May 22 /PRNewswire-FirstCall/ -- SuperGen, Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies, today announced that Michael Molkentin, C.P.A., Chief Financial Officer and Corporate Secretary, and Michael V. McCullar, Ph.D., M.B.A., Vice President of Drug Discovery Operations, are scheduled to co-present at FBR Capital Markets 12th Annual Spring Investor Conference on May 29, 2008 at The Grand Hyatt in New York.

SuperGen's presentation at FBR Capital Markets 12th Annual Spring Investor Conference is scheduled to begin at 10:30 a.m. EDT (7:30 a.m. PDT). A live webcast of the presentation will be available on the investor relations section of the Company's Web site at http://www.supergen.com. A webcast replay of the presentation will be available shortly following the live event.

About SuperGen

Based in Dublin, Calif., SuperGen, Inc. is a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies. SuperGen is developing a number of therapeutic anticancer products focused on kinase and cell signaling inhibitors and DNA methyltransferase inhibitors. For more information about SuperGen, please visit http://www.supergen.com.

Contacts

Timothy L. Enns Mary M. Vegh

SuperGen, Inc. SuperGen, Inc.

SVP, Corporate Communications & Manager, Investor Relations

Business Development T
'/>"/>

SOURCE SuperGen, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Dr. Audrey F. Jakubowski of SuperGen Retires as Chief Regulatory and Quality Officer
2. SuperGen to Present at Thomas Weisel Partners Healthcare Conference September 5th
3. SuperGen to Announce 2007 Fourth Quarter and Fiscal Year-End Financial Results March 3, 2008
4. SuperGen Reports 2007 Fourth Quarter and Annual Financial Results
5. SuperGen to Announce 2008 First Quarter Financial Results April 28, 2008
6. SuperGen to Webcast 3rd Annual Analyst Day on April 29, 2008
7. SuperGen Reports 2008 First Quarter Financial Results
8. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
9. Avicena Group to Present at Noble Financial Conference
10. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
11. Strategic Diagnostics to Present at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Northwest Biotherapeutics (NASDAQ: NWBO ) ... personalized immune therapies for solid tumor cancers, announced today ... American Society Of Clinical Oncology (ASCO) meeting in ... in immune therapy.  (Logo: http://photos.prnewswire.com/prnh/20110329/SF73084LOGO ) ... pre-eminent conference focused on clinical treatment of cancer, with ...
(Date:5/23/2013)... 2013 Pusan National University Yangsan Hospital, ... and contract research company focused on research and ... today a publication reporting the induction of functional ... and immunotherapeutic vaccinia JX-594 (pexastimogene devacirepvec; Jennerex Inc.). ... the May 15 th , 2013 issue of ...
(Date:5/23/2013)... 2013 Watlow®, an industry leader ... systems, recently introduced its new catalog, Watlow® Heating ... in designing and manufacturing industrial heaters, Watlow provides ... serve diverse customer needs. , A description of ... beginning of the book. These options allow high ...
(Date:5/22/2013)... (PRWEB) May 22, 2013 iLuv Creative ... of accessories for the mobile lifestyle, announces they are ... protect, and manage multiple iPad devices efficiently. Winner of ... the 2012 Good Design award, MultiCharger-X is revolutionizing the ... wherever it is deployed. , MultiCharger-X (iAD910) ...
Breaking Biology Technology:NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 3Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 2Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 3Watlow Introduces Its New Industrial Heater Catalog 2iLuv Now Shipping the All New MultiCharger-X 2iLuv Now Shipping the All New MultiCharger-X 3
... , MONROVIA, Calif., June 11 STAAR Surgical Company ... and marketer of minimally invasive ophthalmic products, today announced ... Epiphany Injector System for use with the Affinity(TM) Collamer(R) ... of the Epiphany will usher in a new era ...
... COLLEGEVILLE, Pa., June 11 New data from ... that Wyeth,s (NYSE: WYE ) investigational pneumococcal vaccine, ... potential to provide coverage against the 13 most prevalent serotypes ... death in children younger than five worldwide. , ...
... HONG KONG, June 11 /PRNewswire-Asia/ -- With ... week, Filligent, the Australian-led biotech company,is mobilizing stocks of ... A (H1N1) across Australia. The BioMask is the first ... seconds of contact while retaining,the breathability required by front-line ...
Cached Biology Technology:STAAR Surgical Receives FDA Clearance for the Epiphany(TM) Injector System 2STAAR Surgical Receives FDA Clearance for the Epiphany(TM) Injector System 3New Phase 3 Data Continue to Indicate that Wyeth's Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease 2New Phase 3 Data Continue to Indicate that Wyeth's Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease 3New Phase 3 Data Continue to Indicate that Wyeth's Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease 4New Phase 3 Data Continue to Indicate that Wyeth's Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease 5New Phase 3 Data Continue to Indicate that Wyeth's Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease 6Australia: Face Mask That Kills Swine Flu Readied for Australian Pandemic Fight 2Australia: Face Mask That Kills Swine Flu Readied for Australian Pandemic Fight 3Australia: Face Mask That Kills Swine Flu Readied for Australian Pandemic Fight 4
(Date:5/23/2013)... wrapping of genomic DNA around nucleosomes in the ... A team of Ludwig-Maximilians-Universitaet (LMU) in Munich now ... be locally displaced from nucleosomes for transcription. , ... in the cell nucleus, wrapped around disk-shaped particles ... four different histone proteins and accommodating two loops ...
(Date:5/23/2013)... WASHINGTON Given the implications for the overall ... should play a primary role in ensuring that ... least 60 minutes per day of vigorous or ... the Institute of Medicine. Recent estimates suggest ... this evidence-based guideline for promoting better health and ...
(Date:5/23/2013)... or harsh treatments because science fails to identify ... the disease. Researchers at Case Western Reserve University ... that allows patients to safely choose to do ... drastic measures. , The project is one of ... engineering at Case Western Reserve and director of ...
Breaking Biology News(10 mins):Biochemistry: Unspooling DNA from nucleosomal disks 2Schools should provide opportunities for 60 minutes of daily physical activity to all students 2Schools should provide opportunities for 60 minutes of daily physical activity to all students 3Using big data to identify prostate cancers and best treatments 2Using big data to identify prostate cancers and best treatments 3
... In a paper available at the online site of ... of UCLA researchers reports for the first time that ... stimulating production of the antimicrobial protein cathelicidin. The ... active form of vitamin D, leading to production of ...
... basic molecules that make up all living things have ... people are right- or left-handed. This chirality has a ... living organisms. The inception of chirality from the elementary ... mysteries of the origin of life. Scientists at ...
... granted to start the first safety and tolerability trial ... an incurable, paralyzing neurodegenerative disorder that strikes 5 persons ... in the most active period of their lives − ... previously shown the possibilities for the use of VEGF ...
Cached Biology News:Argonne scientists discover possible mechanism for creating 'handedness' in biological molecules 2First trial in patients with a potential treatment of the incurable ALS muscle disease 2First trial in patients with a potential treatment of the incurable ALS muscle disease 3
Dual Color Mouse anti-Human Anti-Kappa FITC/CD19 PE Class: Antibody Product Group: Immunogluobulin...
Fluorescein isothiocyanate (FITC) mouse anti-human IFN-alpha2 50 ug...
Mouse monoclonal [M7-PB-E9] to pan alpha Sodium Potassium ATPase ( Abpromise for all tested applications)....
Transcription factor Sp2. [Source:Uniprot/SWISSPROT;Acc:Q02086] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Biology Products: